PURPOSE: We investigate the use of 4-phase computerized tomography with intravenous contrast to help distinguish oncocytoma from renal cell carcinoma (RCC) in tumors <4 cm. METHODS: We retrospectively identified patients who underwent surgical management for renal tumors <4 cm from 2005 to 2008. Patients who had pre-operative CT evaluation as per our institution's renal mass protocol and had confirmed pathological diagnosis of either oncocytoma or RCC were included in the study. Enhancement readings were obtained for the tumor and the renal cortex using the same slice simultaneously. RESULTS: Our cohort involved 69 patients (46 men, 23 women; mean age 66) who presented with 79 renal masses. Histopathologically 40 were clear cell, 22 papillary, 5 chromophobe RCC and 12 oncocytoma. On the arterial, venous and delayed phase images, oncocytoma showed the highest mean enhancement change, i.e.,546, 396 and 239% followed by clear cell RCC 261, 261 and 174%, chromophobe RCC 147, 127 and 66% and papillary RCC 137, 184 and 118%, respectively. The enhancement pattern differed significantly on comparing oncocytoma with RCC (P < 0.007). The mean percentage contrast excreted at the end of the delayed phase was 33.3, 13.8, 32 and 53% for clear cell, papillary, chromophobe and oncocytoma, respectively. CONCLUSION: The enhancement and washout values in Hounsfield units obtained by multiphasic CT scan aid in distinguishing oncocytoma from the commonly seen subtypes of RCC in renal masses <4 cm. This preliminary study demonstrates that arterial phase enhancement greater than 500% and washout values of greater than 50% are exclusively seen in renal oncocytomas.
PURPOSE: We investigate the use of 4-phase computerized tomography with intravenous contrast to help distinguish oncocytoma from renal cell carcinoma (RCC) in tumors <4 cm. METHODS: We retrospectively identified patients who underwent surgical management for renal tumors <4 cm from 2005 to 2008. Patients who had pre-operative CT evaluation as per our institution's renal mass protocol and had confirmed pathological diagnosis of either oncocytoma or RCC were included in the study. Enhancement readings were obtained for the tumor and the renal cortex using the same slice simultaneously. RESULTS: Our cohort involved 69 patients (46 men, 23 women; mean age 66) who presented with 79 renal masses. Histopathologically 40 were clear cell, 22 papillary, 5 chromophobe RCC and 12 oncocytoma. On the arterial, venous and delayed phase images, oncocytoma showed the highest mean enhancement change, i.e.,546, 396 and 239% followed by clear cell RCC 261, 261 and 174%, chromophobe RCC 147, 127 and 66% and papillary RCC 137, 184 and 118%, respectively. The enhancement pattern differed significantly on comparing oncocytoma with RCC (P < 0.007). The mean percentage contrast excreted at the end of the delayed phase was 33.3, 13.8, 32 and 53% for clear cell, papillary, chromophobe and oncocytoma, respectively. CONCLUSION: The enhancement and washout values in Hounsfield units obtained by multiphasic CT scan aid in distinguishing oncocytoma from the commonly seen subtypes of RCC in renal masses <4 cm. This preliminary study demonstrates that arterial phase enhancement greater than 500% and washout values of greater than 50% are exclusively seen in renal oncocytomas.
Authors: Sung S Kim; Yoo D Choi; Xue M Jin; Yong M Cho; Ja J Jang; Sang W Juhng; Chan Choi Journal: Histopathology Date: 2009-03-19 Impact factor: 5.087
Authors: Fredrik Petersson; Zoran Gatalica; Petr Grossmann; Maria Delia Perez Montiel; Isabel Alvarado Cabrero; Stela Bulimbasic; Anthony Swatek; Lubomir Straka; Tomas Tichy; Milan Hora; Naoto Kuroda; Ben Legendre; Michal Michal; Ondrej Hes Journal: Virchows Arch Date: 2010-03-19 Impact factor: 4.064
Authors: Uyen N Hoang; S Mojdeh Mirmomen; Osorio Meirelles; Jianhua Yao; Maria Merino; Adam Metwalli; W Marston Linehan; Ashkan A Malayeri Journal: Abdom Radiol (NY) Date: 2018-12
Authors: Jay Amin; Bo Xu; Shervin Badkhshan; Terrance T Creighton; Daniel Abbotoy; Christine Murekeyisoni; Kristopher M Attwood; Thomas Schwaab; Craig Hendler; Michael Petroziello; Charles L Roche; Eric C Kauffman Journal: Clin Cancer Res Date: 2018-05-11 Impact factor: 12.531
Authors: Boon Chye Ching; Hui Shan Tan; Puay Hoon Tan; Chee Keong Toh; Ravindran Kanesvaran; Quan Sing Ng; Min Han Tan Journal: Singapore Med J Date: 2016-04-19 Impact factor: 1.858
Authors: Phillip M Pierorazio; Elias S Hyams; Salina Tsai; Zhaoyong Feng; Bruce J Trock; Jeffrey K Mullins; Pamela T Johnson; Elliot K Fishman; Mohamad E Allaf Journal: Urology Date: 2013-04-17 Impact factor: 2.649